Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015380 | 0.88 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL2014665 | 0.77 | CYP2C9 (0.32) | — | |
| Hydrochloric Acid SCHEMBL10749226 | 0.74 | CYP2C9 (0.30) | — | |
| SCHEMBL80949 | 0.74 | — | — | |
| SCHEMBL85855 | 0.74 | — | — | |
| SCHEMBL1489684 | 0.74 | — | — | |
| SCHEMBL83315 | 0.74 | — | — | |
| SCHEMBL239626 | 0.74 | — | — | |
| SCHEMBL81766 | 0.74 | — | — | |
| SCHEMBL4370975 | 0.74 | S1PR2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738647-B2 | Methods for the synthesis of polycyclic guanidine compounds | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2017-08-22 | — | — | US | claimed |
| US-20140194622-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2014-07-10 | — | — | US | claimed |
| EP-2515648-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | Novomer, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120259112-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2012-10-11 | — | — | US | claimed |
| WO-2011079041-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2011-06-30 | — | — | WO | claimed |
| US-9738647-B2 | Methods for the synthesis of polycyclic guanidine compounds | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2017-08-22 | — | — | US | disclosed |
| EP-2515648-B1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20140194622-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8642771-B2 | Methods for the synthesis of polycyclic guanidine compounds | NOVOMER, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2515648-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | Novomer, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120259112-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2011079041-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194622-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | GNMT, GMPS, GDA | SIGMAR1 2881/4885 |
| US-20120259112-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | GNMT, GMPS, GDA | SIGMAR1 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.